Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01204723 · ClinicalTrials.gov registry record · Phase 1
Medications Development for the Treatment of Cannabis Related Disorders
A Phase 1 study, sponsored by University of Virginia.
- Completed
- Registry status
- Phase 1
- Development phase
- 63
- Enrollment target
NCT01204723 is a Phase 1 study that has completed, run by University of Virginia. The registered enrollment target is 63 participants.
The verdict
NCT01204723, a Phase 1 study, has completed, sponsored by University of Virginia.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 63 participants
- Enrollment target
Study Summary
The primary objective of this application is to test the neurobehavioral mechanisms and effects of aprepitant as a new cessation agent for cannabis, tobacco or both.
Interventions
- DRUG Placebo Aprepitant
- DRUG Active Aprepitant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2009-08 |
| Est. Completion | 2012-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01204723
The ClinicalTrials.gov registry entry for NCT01204723 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Aprepitant is the first listed.
NCT01204723 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01204723 about?
NCT01204723 is a clinical study titled "Medications Development for the Treatment of Cannabis Related Disorders". The primary objective of this application is to test the neurobehavioral mechanisms and effects of aprepitant as a new cessation agent for cannabis, tobacco or both.
What is the current status of trial NCT01204723?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2009-08. Estimated completion is 2012-04.
What interventions are being tested in trial NCT01204723?
The interventions under investigation include: Placebo Aprepitant (DRUG), Active Aprepitant (DRUG).
Who is sponsoring clinical trial NCT01204723?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.